S&P Global Ratings downgraded Embecta Corp. (NYSE:EMBC) to a 'B' corporate credit rating from 'B+' and lowered its issue-level ratings on the company's senior secured notes to 'B' from 'B+'. The ratings firm assigned a stable outlook following the downgrade.
The move follows a 14% decline in revenue reported by Embecta in its second fiscal quarter of 2026. S&P attributed the decline primarily to a deterioration in demand for the company’s core product line of insulin pen needles and to the loss of share at one of Embecta’s larger customers, which switched some demand to a lower-cost provider.
Embecta's insulin pen needle sales dropped roughly 20% on a constant-currency basis in the quarter ended March 31, 2026, according to S&P. The ratings agency said the sales shortfall reflected two elements: competitive displacement at a major retail customer and weaker overall U.S. market demand for pen needles.
S&P detailed several factors it sees weighing on U.S. demand for pen needles: regulatory changes that S&P says have reduced insulin use, a move by patients and payors toward lower-cost retail channels, broader penetration of automated insulin delivery devices, and increased use of GLP-1 drugs that can reduce the need for insulin injections. In addition to its pen needle business, Embecta reported about a 15% constant-currency revenue decline in its smaller syringes segment and a decline in contract manufacturing revenue.
As a consequence of the revenue deterioration and the resulting loss of manufacturing operating leverage, S&P projects pressure on profitability. The ratings firm estimates that adjusted margins will fall by roughly 800 basis points to about 29% in fiscal 2026, down from 37% in fiscal 2025.
On leverage, S&P expects Embecta's debt burden to increase to between 4.5x and 5x over fiscal 2026-2027, which is above the 4x threshold that supported the company's prior rating. Despite the downgrade, S&P assigned a stable outlook, reflecting its expectation that Embecta will keep leverage below 5x over the next two years by directing some free cash flow toward debt repayment.
The ratings agency's fiscal 2026 revenue forecast calls for an approximate 6% decline in total sales. That projection incorporates an 8%-10% organic revenue contraction, an estimated $30 million in revenue from Embecta's expected acquisition of Owen Mumford by the end of May 2026, and a modest foreign currency tailwind.
S&P also outlined assumptions about how Embecta will finance the acquisition of Owen Mumford. The agency assumes the company will draw on its revolving credit facility to fund the purchase and will reduce its dividend after closing to prioritize debt reduction.
Context and implications
S&P's downgrade reflects a combination of product-specific competitive pressure and secular shifts in diabetes treatment and distribution that have reduced demand for pen needles. The ratings firm's financial projections suggest lower revenue, compressed margins, and higher leverage in fiscal 2026 and 2027, even after accounting for the planned acquisition and anticipated currency effects.
Investors and market participants will likely monitor upcoming quarterly results, integration progress related to Owen Mumford, and any changes to Embecta's capital allocation - including dividend policy and debt repayment - that influence the company's leverage trajectory.